Important Notice for Geron Corporation Shareholders: Potential Class Action Lawsuit
New York, NY – The Gross Law Firm, a leading national securities fraud law firm, is investigating potential securities fraud on behalf of shareholders of Geron Corporation (NASDAQ: GERN). The investigation focuses on allegations that Geron may have issued materially misleading business information to the public during the class period, which is defined as February 1, 2023, to March 30, 2025.
Class Period and Eligibility
If you purchased or otherwise acquired Geron shares during the class period, you may be a potential class member in this action. The Gross Law Firm encourages you to contact the firm as soon as possible so that you can be apprised of any important developments and receive information about how to protect your investments.
Background
Geron is a biotechnology company that focuses on developing therapeutics for aging and age-related diseases. The company’s lead product candidate is imetelstat, a first-in-class therapeutic that targets the enzyme telomerase. Imetelstat is being studied for the treatment of myelofibrosis and other hematologic malignancies.
Allegations of Securities Fraud
The Gross Law Firm’s investigation focuses on Geron’s public statements during the class period regarding the progress and prospects of its clinical trials for imetelstat. Specifically, the firm is investigating whether Geron misrepresented the safety and efficacy data from these trials, as well as the regulatory pathway for imetelstat’s approval.
Potential Impact on Shareholders
If it is determined that Geron issued materially misleading information during the class period, shareholders may be able to recover their losses through a class action lawsuit. The extent of these losses will depend on the specific facts and circumstances of each case.
Potential Impact on the Biotech Industry
The potential fallout from this investigation could extend beyond Geron and impact the biotech industry as a whole. If it is shown that Geron engaged in securities fraud, it could raise questions about the reliability of other companies’ clinical trial data and regulatory filings. This could lead to increased scrutiny and potential regulatory action, as well as increased litigation risk for biotech companies.
Next Steps
If you are a Geron shareholder and believe you may be a potential class member, the Gross Law Firm encourages you to contact the firm as soon as possible. You may be entitled to compensation for your losses, and the firm can help you understand your legal rights and options.
- Call The Gross Law Firm at 888-227-1231
- Visit the firm’s website at
- Email the firm at [email protected]
The Gross Law Firm represents shareholders nationwide and prides itself on its commitment to excellence and dedication to obtaining the best possible results for its clients.
This press release does not constitute an offer or solicitation of business or legal advice. It is for informational purposes only.
Conclusion
The Gross Law Firm’s investigation into Geron Corporation’s public statements during the class period raises important questions about the reliability of clinical trial data and regulatory filings in the biotech industry. If it is determined that Geron engaged in securities fraud, it could have significant implications for shareholders and the industry as a whole. Shareholders who purchased Geron shares during the class period are encouraged to contact the firm to discuss their legal rights and options.
